ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0699

Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review
Abstract Number: 1625

Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Abstract Number: 1298

Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
Abstract Number: 1310

Clinical Characteristics of Patients with SpA and Concomitant IBD: Results from the ASAS PerSpA Study
Abstract Number: 0446

Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Abstract Number: 1528

Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
Abstract Number: 1544

Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study
Abstract Number: 1632

Clinical Features and Colchicine Response in Patients with Undifferentiated Systemic Autoinflammatory Disease Carrying E148Q vs. Other MEFV Mutations
Abstract Number: 0687

Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis
Abstract Number: 1409

Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients
Abstract Number: 1457

Clinical Heterogeneity of the VEXAS Syndrome: A Case Series
Abstract Number: 0122

Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial
Abstract Number: 1638

Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease
Abstract Number: 1278

Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
Abstract Number: 0700

Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].